• 尊龙凯时

    SynRx Therapeutics Partners with Venture Capital to Open a New Chapter in the Development of Innovative Drugs for DNA Damage Repair
    SynRx Release time:2021-12-30 SynRx Source:SynRx SynRx Pageviews:1219

        At the end of 2021, SynRx Therapeutics completed a PRE-A round of financing, which was led by Haibang Fenghua Venture Capital  with a number of well-known investment institutions including Westlake Innovation Capital in participation.


         This round of financing is mainly utilized for the establishment of the company's branch in Shanghai, the construction of laboratories , the product pipeline development for each project, and the introduction of high-educated domestic and foreign talents.


        Founded in August 2021, SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in-class, anti-tumor compounds, and preclinical studies are in progress .


    SynRx
    Business Development bd@mini818.com
    Careers hr@mini818.com
    Address @ Room 201, Building 4, 1390 Cangxing Street, Cangqian Subdistrict, Yuhang District, Hangzhou, Zhejiang @ Room 303, No.1, Lane 88, Shengrong Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai
    CopyRight 2022 All Right Reserved SynRx Therapeutics 浙ICP备2021033925号 SiteMap
    SynRx
    SynRx
    SynRx
    0571-86360796
    SynRx